NASDAQ$ENTA
Enanta Pharmaceuticals Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Enanta Pharmaceuticals reported financial results for its fiscal fourth quarter and year ended September 30, 2023.
Enanta Pharmaceuticals reported a revenue of $18.9 million for the quarter ended September 30, 2023, compared to $20.3 million for the same period in 2022. The net loss for the quarter was $28.1 million, or $1.33 per diluted common share, compared to a net loss of $26.3 million, or $1.27 per diluted common share, for the corresponding period in 2022. Cash, cash equivalents, and marketable securities totaled $370.0 million at September 30, 2023.
- Initiated a Phase 2a Challenge Study of EDP-323, an L-Protein Inhibitor, in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV); Expect to Report Data in Q3 2024
- Streamlined Business and Significantly Lowered 2024 R&D and G&A Spending Guidance to Support Ongoing Operations
- Cash and Marketable Securities Totaled $370 Million at September 30, 2023
- Advancing RSVPEDs and RSVHR, ongoing Phase 2 trials of EDP-938, with a data readout from at least one of these studies in the third quarter of 2024.
Headline financials
Revenue & EPS history
Enanta Pharmaceuticals · Revenue · Quarterly
$18.9M
Revenue by segment
Enanta Pharmaceuticals · $18.9M total across 1 segment · Q3 2023
- Royalty Revenue$18.9M-3.0%100.0%
Forward guidance
Enanta expects that its current cash, cash equivalents and short-term marketable securities, as well as its continuing retained portion of royalty revenue, will continue to be sufficient to meet the anticipated cash requirements of its existing business and development programs through fiscal 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
-1.3%
Avg return
Earnings day
-1.2%
Avg return
5 days after
-1.0%
Avg return
30 days after
41%
24 / 58 earnings
Positive
+14.8%
Q4 2021
Best reaction
-29.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -6.1% | -13.4% | -26.0% | |
| Q1 2026 | +2.2% | +0.1% | -3.0% | |
| Q4 2025 | -3.5% | -0.7% | +13.3% | |
| Q2 2025 | -5.6% | +3.6% | +33.5% | |
| Q1 2025 | +14.1% | +45.7% | +39.4% | |
| Q4 2024 | -8.4% | -7.9% | -34.7% | |
| Q3 2024 | -6.5% | -9.5% | -12.7% | |
| Q2 2024 | -13.6% | -16.6% | -18.3% | |
| Q1 2024 | -1.4% | -1.7% | +22.8% | |
| Q4 2023 | +9.2% | +8.9% | -6.7% | |
| Q3 2023 | -6.6% | -19.8% | -38.8% | |
| Q2 2023 | -29.2% | -29.7% | -27.0% | |
| Q1 2023 | -0.5% | +0.2% | -12.1% | |
| Q4 2022 | -2.9% | -11.2% | +0.3% | |
| Q3 2022 | -3.8% | -4.2% | -10.4% | |
| Q2 2022 | -1.9% | -13.2% | -24.4% | |
| Q1 2022 | +2.8% | +1.8% | +3.9% | |
| Q4 2021 | +14.8% | +22.0% | +2.7% | |
| Q3 2021 | +5.6% | +6.3% | +35.8% | |
| Q2 2021 | -6.9% | -5.6% | -8.5% | |
| Q1 2021 | +3.1% | -3.3% | -3.9% | |
| Q4 2020 | -1.6% | -1.5% | -2.9% | |
| Q3 2020 | -2.1% | +0.2% | +4.4% | |
| Q2 2020 | -0.6% | +1.8% | -0.5% | |
| Q1 2020 | -0.1% | -5.4% | -2.3% | |
| Q4 2019 | -1.8% | +1.1% | +3.4% | |
| Q3 2019 | +6.0% | +7.4% | +0.7% | |
| Q2 2019 | -0.0% | -3.2% | +0.5% | |
| Q1 2019 | +11.6% | +11.2% | +22.9% | |
| Q4 2018 | +1.5% | +0.2% | -11.1% | |
| Q3 2018 | -6.4% | -6.3% | -11.4% | |
| Q2 2018 | -4.5% | -3.6% | +7.7% | |
| Q1 2018 | -19.0% | -16.7% | -7.5% | |
| Q4 2017 | -5.9% | -1.4% | +18.0% | |
| Q3 2017 | +2.2% | +2.0% | +11.6% | |
| Q2 2017 | +9.3% | +8.0% | -3.3% | |
| Q1 2017 | -6.5% | -7.5% | -8.9% | |
| Q4 2016 | +7.4% | +9.0% | +10.0% | |
| Q3 2016 | +2.3% | +6.4% | +4.3% | |
| Q2 2016 | -1.8% | — | — | |
| Q1 2016 | +1.8% | — | — | |
| Q4 2015 | -2.0% | — | — | |
| Q3 2015 | -13.8% | — | — | |
| Q2 2015 | -0.1% | — | — | |
| Q1 2015 | -4.2% | — | — | |
| Q4 2014 | +4.3% | — | — | |
| Q3 2014 | +4.6% | — | — | |
| Q2 2014 | +5.2% | — | — | |
| Q1 2014 | -3.6% | — | — | |
| Q1 2013 | -3.6% | — | — | |
| Q4 2011 | -22.6% | — | — | |
| Q1 2012 | -22.6% | — | — | |
| Q4 2013 | +8.5% | — | — | |
| Q3 2013 | +7.4% | — | — | |
| Q3 2012 | +7.4% | — | — | |
| Q2 2012 | +5.5% | — | — | |
| Q4 2012 | +5.5% | — | — | |
| Q2 2013 | +0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro